This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Signs That Your Trading Will Ruin Your Retirement - July 08, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
The Zacks Analyst Blog Highlights: Alibaba, NVIDIA, Bristol Myers Squibb, PetroChina and S&P Global
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, NVIDIA, Bristol Myers Squibb, PetroChina and S&P Global
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Bristol Myers Squibb (BMY) closed at $60.29 in the latest trading session, marking a +0.17% move from the prior day.
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
Top Stock Reports for Alibaba, NVIDIA & Bristol Myers Squibb
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), NVIDIA (NVDA) and Bristol Myers Squibb (BMY).
Seattle Genetics' Adcetris Progresses Well Amid Competition
by Zacks Equity Research
Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. Further, label expansions of the drug should continue to boost the top line.
5 High Earnings Yield Stocks for a Winning Portfolio
by Zacks Equity Research
Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
by Kinjel Shah
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Powerful Proof Anyone Can Invest for an Early Retirement - July 02, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Is Bristol Myers (BMY) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Bristol Myers (BMY) could produce exceptional returns because of its solid growth attributes.
BMY or AZN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMY vs. AZN: Which Stock Is the Better Value Option?
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
by Zacks Equity Research
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
Pfizer's sBLA for Bavencio Gets FDA Nod, Daurismo Gets EU Nod
by Zacks Equity Research
The FDA approves Pfizer (PFE) and Merck KGaA's sBLA for Bavencio as a first-line maintenance therapy for metastatic urothelial carcinoma. Daurismo gets the EU nod for acute myeloid leukemia.
Markets Book Best Quarterly Gains in 20 Years: 4 Stocks to Buy
by Zacks Equity Research
With the Dow and the S&P 500 booking their best quarterly performance since 1987, one could consider stepping into the markets again with an investment perspective.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.80, marking a +1.73% move from the previous day.
Signs That Your Trading Will Ruin Your Retirement - June 30, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - June 30, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Top Ranked Growth Stocks to Buy for June 30th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 30th.
Is Bristol Myers Squibb (BMY) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bristol Myers & Acceleron Obtain EC Approval for Reblozyl
by Zacks Equity Research
Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.
Top Ranked Growth Stocks to Buy for June 29th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 29th
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks - June 24, 2020
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Simple Secrets Anyone Can Use to Reach Early Retirement - June 24, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.38, marking a +1.42% move from the previous day.
Bristol Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy? (Revised)
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol Myers Squibb (BMY) have what it takes? Let's find out.